Si prevede che il mercato dell’omocistinuria raggiungerà i 73,96 milioni di dollari entro il 2028 rispetto ai 56,58 milioni di dollari del 2021; si stima che crescerà a un CAGR del 3,9% nel periodo 2021-2028.
L'omocistinuria è una condizione genetica in cui il corpo non è in grado di digerire correttamente alcuni elementi costitutivi delle proteine (amminoacidi). L'omocistinuria è disponibile in vari tipi, ciascuno con il proprio insieme di segni e sintomi, nonché un'eziologia ereditaria. La miopia (miopia), la dislocazione del cristallino nella parte anteriore dell'occhio, un maggior rischio di coagulazione irregolare del sangue e ossa fragili soggette a fratture (osteoporosi) o altre anomalie scheletriche definiscono la forma più diffusa di omocistinuria. Alcune delle persone colpite presentano anche ritardi nello sviluppo e difficoltà di apprendimento.
Personalizza la ricerca in base alle tue esigenze
Possiamo ottimizzare e personalizzare l'analisi e l'ambito che non sono soddisfatti dalle nostre offerte standard. Questa flessibilità ti aiuterà a ottenere le informazioni esatte necessarie per la pianificazione aziendale e il processo decisionale.
Mercato dell’omocistinuria: approfondimenti strategici
CAGR (2021 - 2028)3,9%- Dimensione del mercato 2021:
56,58 milioni di dollari - Dimensione del mercato nel 2028:
73,96 milioni di dollari
Dinamiche di mercato
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
Giocatori chiave
- BASF SE
- FARMACEUTICO HUAZHONG
- Pfizer Inc.
- MYLAN NV
- Aeglea BioTherapeutics
- Amino GmbH
- KAO Corporation
- DSM Corporation
- Tecnologie orfane
Panoramica regionale
- Nord America
- Europa
- Asia-Pacifico
- America meridionale e centrale
- Medio Oriente e Africa
Segmentazione del mercato
Metodo- Diagnostica e trattamento
Utente finale- Ospedali e cliniche
- Laboratori di Diagnostica e per Immagini
- Cliniche specialistiche
- Istituti accademici e di ricerca
Geografia- Nord America
- Europa
- Asia Pacifico
- Medio Oriente e Africa
- America meridionale e centrale
- Il PDF di esempio mostra la struttura del contenuto e la natura delle informazioni con analisi qualitative e quantitative.
La crescita del mercato dell’omocistinuria è attribuita alle crescenti carenze di vitamina B6 e vitamina B12 e alla crescente prevalenza di disturbi metabolici ereditari. Tuttavia, la mancanza di consapevolezza su varie malattie rare e disturbi metabolici ereditari ostacola la crescita del mercato.
Approfondimenti di mercato
L’aumento delle carenze di vitamina B6 e vitamina B12 guida il mercato dell’omocistinuria
L’aumento dei modelli di carenza di vitamina B6 e vitamina B12 porta a diversi disturbi come anemia, anemia megaloblastica, anemia microcitica e alcuni tipi di disturbi metabolici, che dovrebbero stimolare la crescita del mercato durante il periodo di previsione. Poiché si ritiene che la terapia con vitamina B6 sia una terapia efficace contro l'omocistinuria, la carenza di questa vitamina può peggiorare la condizione. La piridossina (vitamina B6) agisce come cofattore della beta-sintasi e agisce come chaperone per stabilizzare diverse mutazioni missenso. Alcuni pazienti con omocistinuria rispondono bene alla terapia con piridossina e questa aiuta ad abbassare i livelli di omocisteina, fornendo così sollievo dalla condizione. Pertanto, la vitamina B6 è considerata vitale nella gestione dell’omocistinuria poiché è disponibile un numero limitato di trattamenti per curare la condizione. La carenza di questo enzima porta ad anemia e anemia microcitica. Si prevede che la crescente prevalenza dell’anemia stimolerà la crescita del mercato durante il periodo di previsione. Secondo l'Organizzazione Mondiale della Sanità, ad esempio, l'anemia colpisce oltre 1,62 miliardi di persone, ovvero il 24,8% della popolazione. Le principali cause dell’anemia sono una dieta scorretta e le carenze di vitamine come B6, B9 e B12. Prevalentemente, la carenza di vitamina B6 è una delle principali cause di anemia. Pertanto, si prevede che un aumento dei casi di carenza di vitamina B6 e un’elevata prevalenza di disturbi associati alla sua carenza sosterranno la crescita del mercato durante il periodo di previsione.
Approfondimenti basati sul metodo
Il mercato globale dell’omocistinuria, basato sul metodo, è diviso in trattamento e diagnostica. Il segmento del trattamento deteneva una quota maggiore del mercato nel 2021. Inoltre, si prevede che lo stesso segmento registrerà un CAGR più elevato nel mercato durante il periodo di previsione a causa dell’uso dominante del trattamento e della crescente ricerca e sviluppo di nuovi trattamenti per l’omocistinuria.
Ambito del rapporto di mercato Omocistinuria
| Attributo del rapporto | Dettagli |
|---|---|
| Dimensioni del mercato nel 2021 | 56,58 milioni di dollari |
| Dimensioni del mercato entro il 2028 | 73,96 milioni di dollari |
| CAGR globale (2021-2028) | 3,9% |
| Dati storici | 2019-2020 |
| Periodo di previsione | 2022-2028 |
| Segmenti coperti | Per metodo
|
| Regioni e paesi coperti | Nord America
|
| Leader di mercato e profili aziendali chiave |
|
- Il PDF di esempio mostra la struttura del contenuto e la natura delle informazioni con analisi qualitative e quantitative.
Approfondimenti basati sull'utente finale
Il mercato globale dell’omocistinuria, in base all’utente finale, è segmentato in laboratori di diagnostica e imaging, ospedali e cliniche, cliniche specialistiche e istituti accademici e di ricerca. Nel 2021, il segmento dei laboratori di diagnostica e imaging deteneva la quota maggiore del mercato. Inoltre, si prevede che il segmento registrerà il CAGR più elevato, pari al 4,2%, nel periodo 2021-2028 a causa della crescente diagnosi di disturbi metabolici ereditari nei laboratori di diagnostica e di imaging.
Il lancio e l’approvazione dei prodotti sono strategie comunemente adottate dalle aziende per espandere la propria presenza globale e i portafogli di prodotti. Inoltre, gli attori del mercato dell’omocistinuria si concentrano sulla strategia di partnership per ampliare la propria clientela, che, a sua volta, consente loro di mantenere il proprio marchio in tutto il mondo.
Il rapporto segmenta il mercato dell’omocistinuria come segue
Mercato dell’omocistinuria – per metodo
- Trattamento
- Piridossina
- Betaina
- Altri
- Diagnostica
- Test genetici
- Test di screening degli aminoacidi
- Test degli enzimi epatici
- Altri
Mercato dell’omocistinuria – per utente finale
- Ospedali e cliniche
- Laboratori di Diagnostica e per Immagini
- Cliniche specialistiche
- Istituti accademici e di ricerca
Mercato dell’omocistinuria – per geografia
- Nord America
- NOI
- Canada
- Messico
- Europa
- UK
- Germania
- Francia
- Italia
- Spagna
- Resto d'Europa
- Asia Pacifico
- Cina
- Giappone
- India
- Australia
- Corea del Sud
- Resto dell'Asia Pacifico
- Medio Oriente e Africa
- Emirati Arabi Uniti
- Arabia Saudita
- Sud Africa
- Resto del Medio Oriente e dell'Africa
- America meridionale e centrale
- Brasile
- Argentina
- Resto dell'America meridionale e centrale
Profili aziendali
- BASF SE
- FARMACEUTICO HUAZHONG
- Pfizer Inc.
- MYLAN NV
- Aeglea BioTherapeutics
- Amino GmbH
- KAO Corporation
- DSM Corporation
- Tecnologie orfane
- Fresenius Kabi AG
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Asia Pacific region is expected to be the fastest-growing region among all other regions. The market in this region is expected to grow significantly in countries such as, China, Japan and India. The market is driven by increase in prevalence of inherited metabolic disorders, rise in government initiatives to manage rare diseases across the region along with increase in diagnostic tests across the region such as new born screening test etc. Therefore, the region holds huge potential for the homocystinuria market players to grow during the forecast period.
Homocystinuria is an inherited disorder in which the body is unable to process certain building blocks of proteins (amino acids) properly. There are multiple forms of homocystinuria, which are distinguished by their signs and symptoms and genetic cause. The most common form of homocystinuria is characterized by nearsightedness (myopia), dislocation of the lens at the front of the eye, an increased risk of abnormal blood clotting, and brittle bones that are prone to fracture (osteoporosis) or other skeletal abnormalities. Some affected individuals also have developmental delay and learning problems.
The growth of the Homocystinuria market is mainly attributed to factors such as the increasing prevalence of inherited metabolic disorders coupled with rise in vitamin B6 and Vitamin B12 deficiencies. However, the lack of awareness about various rare disorders and inherited metabolic disorders is hindering the market growth.
The global Homocystinuria market is expected to reach US$ 73,960.22 thousand by 2028 from US$ 56,589.20 thousand in 2021; it is estimated to grow at a CAGR of 3.9% during 2021-2028.
Emergence of human enzyme therapeutics and enzyme replacement therapy to treat rare disorders is one of the future trends of homocystinuria market. Enzyme replacement therapy and enzyme therapeutics is a type of novel drug therapy in which therapeutic enzymes are used to treat chronic and life-threatening diseases such as cancer, idiosyncratic disorders, and rare disorders. Furthermore, if an enzyme is not functioning properly in the body, then enzyme replacement therapy is used for replacing the enzyme that is deficient in the body. Enzymes have a predominant role in pharmaceutical industries and drug development as they treat various disorders. The advancements in the field of protein technology, recombinant DNA technology, enzyme immobilization, and nanotechnology have provided a solid platform for the use of enzymes in the treatment of various disorders.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies - Homocystinuria Market
- BASF SE
- HUAZHONG PHARMACEUTICAL
- Pfizer Inc.
- MYLAN N.V
- Aeglea BioTherapeutics
- Amino GMBH
- KAO Corporation
- DSM Corporation
- Orphan Technologies
- Fresenius Kabi AG.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For